Ami Fadia

Shares of AtaiBeckley Inc (NASDAQ:ATAI) continued to rally in early trading on Tuesday after it released Phase 2 trial data for BPL-003 for the treatment of social anxiety disorder. Here are the key analyst insights: Needham analyst Ami Fadia maintained a Buy rating and price target of $14....

Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health. The company’s lead drug candidate, BPL-003, is under development for treatment-resistant depression. • ATAI stock is...

Needham initiated coverage on Monday for GH Research PLC (NASDAQ:GHRS), citing the company’s lead drug candidate, GH-001, which had demonstrated impressive efficacy in Phase 2 versus competition. • GHRS is showing upward movement. See the full breakdown here. Recently, the company...

A physician survey for Neurocrine Biosciences Inc's (NASDAQ:NBIX) Crenessity suggests "strong uptake across all patient segments," according to Needham.  The Neurocrine Biosciences Analyst: Analyst Ami Fadia upgraded the rating from Hold to Buy, while raising the price target to $138. The...

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen Analyst Brian Abrahams maintained an Outperform rating, while raising the price...

It's been about four months since Biogen, Inc. (NASDAQ: BIIB) received approval for its controversial Alzheimer's treatment Aduhelm. The initial broad approval was later narrowed by the FDA. The "Aduhelm opportunity" for the biopharma is underappreciated, an analyst said Thursday...

Amarin Corporation plc (NASDAQ: AMRN) shares were plummeting on above-average volume as an appeal hearing on the Vascepa fish oil capsule patent gets underway.  What Happened: Amarin appealed against a late March ruling that its Vascepa patents were invalid. The invalidation of the patents...

Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa.  The Amarin Analysts: Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating and $35 price...

Amarin Corporation plc (NASDAQ: AMRN) shares, which were higher in after-hours trading Thursday following the company's announcement regarding a third-party pilot trial of its Vascepa in COVID-19, were giving back the gains Friday.  First Vascepa Generic Greenlighted The negative sentiment...

TEVA Pharmaceutical Industries (NASDAQ: TEVA)'s fundamentals have substantially improved over the last few months, giving the stock a more balanced risk-reward profile, according to Leerink.  The Analyst Leerink analyst Ami Fadia upgraded TEVA Pharmaceutical from Underperform to Market...

Mylan NV (NASDAQ: MYL)’s had a rough three years, but one analyst left the pharma company's investor day with fresh optimism. The Rating Leerink analyst Ami Fadia upgraded Mylan from Market Perform to Outperform and maintained a $52 price target. The Thesis By Leerink’s...

Depomed Inc (NASDAQ: DEPO) shares have surged about 25 percent since mid-February, and UBS’ Ami Fadia believes there is limited upside going forward. Fadia downgraded the rating on the company from Buy to Neutral, with a price target of $20. Limited Upside The analyst believes there could be...